UBS Group
RCEL icon

UBS Group’s Avita Medical RCEL Stock Holding History

UBS Group’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Sell
62,454
-27,855
-31% -$117K ﹤0.01% 6553
2025
Q4 		$312K Buy
90,309
+14,909
+20% +$59.5K ﹤0.01% 6341
2025
Q3 		$385K Sell
75,400
-334,399
-82% -$1.74M ﹤0.01% 6270
2025
Q2 		$2.17M Buy
409,799
+65,071
+19% +$473K ﹤0.01% 4735
2025
Q1 		$2.81M Buy
344,728
+216,098
+168% +$2.02M ﹤0.01% 4390
2024
Q4 		$1.65M Buy
128,630
+110,824
+622% +$1.31M ﹤0.01% 4915
2024
Q3 		$191K Buy
17,806
+686
+4% +$6.44K ﹤0.01% 5909
2024
Q2 		$136K Sell
17,120
-34,396
-67% -$327K ﹤0.01% 5948
2024
Q1 		$826K Buy
51,516
+31,509
+157% +$510K ﹤0.01% 4753
2023
Q4 		$274K Buy
20,007
+7,258
+57% +$83.2K ﹤0.01% 5568
2023
Q3 		$186K Sell
12,749
-4,729
-27% -$80K ﹤0.01% 5410
2023
Q2 		$297K Buy
17,478
+11,470
+191% +$168K ﹤0.01% 5210
2023
Q1 		$83.9K Buy
6,008
+5,282
+728% +$56.2K ﹤0.01% 6055
2022
Q4 		$4.79K Buy
726
+476
+190% +$2.85K ﹤0.01% 9278
2022
Q3 		$1K Sell
250
-1,023
-80% -$6.32K ﹤0.01% 10017
2022
Q2 		$6K Sell
1,273
-136
-10% -$840 ﹤0.01% 8711
2022
Q1 		$13K Sell
1,409
-35,820
-96% -$330K ﹤0.01% 8071
2021
Q4 		$445K Buy
37,229
+21,042
+130% +$321K ﹤0.01% 5072
2021
Q3 		$287K Buy
16,187
+14,987
+1,249% +$283K ﹤0.01% 5071
2021
Q2 		$25K Sell
1,200
-12,922
-92% -$255K ﹤0.01% 7112
2021
Q1 		$280K Buy
14,122
+12,271
+663% +$285K ﹤0.01% 5255
2020
Q4 		$35K Buy
1,851
+1,651
+826% +$36.2K ﹤0.01% 6508
2020
Q3 		$5K Sell
200
-959
-83% -$23.9K ﹤0.01% 7328
2020
Q2 		$35K Buy
1,159
+959
+480% +$29.3K ﹤0.01% 6172
2020
Q1 		$6K Sell
200
-871
-81% -$36.1K ﹤0.01% 7229
2019
Q4 		$49K Buy
+1,071
New +$44.5K ﹤0.01% 6359

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's RCEL Position: Q1 2026 in Review

UBS Group reduced its Avita Medical (RCEL) stake by 31% in Q1 2026, selling an estimated $117K and leaving 62,454 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #6553.

UBS Group first reported a position in RCEL in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.81M in Q1 2025. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • UBS Group held 62,454 shares of Avita Medical worth $231K as of Q1 2026.
  • UBS Group sold 27,855 Avita Medical shares in Q1 2026, an estimated $117K.
  • Avita Medical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6553 holding.
  • UBS Group first reported a position in Avita Medical in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's Avita Medical position peaked at $2.81M in Q1 2025.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.